Bank of America Predicts Yen Rebound as USD/JPY Faces Risks 
Nvidia’s China AI Chip Market Share Falls to 34% as Huawei Gains Ground 
Syndax Stock Drops 15% After Axatilimab Trial Failure 
US Stock Futures Rise as Oil Prices Fall Ahead of Q3 Earnings 
South Korea Blocks 27 Crypto Exchange Websites in Regulatory Crackdown 
Nasdaq Faces Pullback to 26,225 Despite Bullish Outlook, UBS Says 
Hong Kong’s Second Solana ETF Launches With Lower Fees 
Deutsche Bank CEO Urges Faster German Economic Reforms 
Airbus Tests Valkyrie Combat Drone in Europe for Eurofighter Integration 
Elon Musk Donates $366 Million to 2026 US Midterms 
Wall Street Ends Mixed as Investors Await CPI and Bank Earnings 
Oil Prices Rise as Houthi Attacks Threaten Middle East Supply 
Gold Prices Rise Above $4,200 as Russia-Ukraine Energy Truce Eases Oil Concerns 
European Auto Stocks Rise as EU-China Trade Deal Targets Hybrid Imports 
RBA Signals More Rate Hikes as Inflation Risks Rise 
Epic Games Delays Disney Shooter, Shifts to AI-First Development 
Oil Prices Surge Above $106 After Deadly Saudi Airport Attack 
Add as a preferred source on Google
Sanofi will be acquiring mRNA developer, Translate Bio, and this was revealed on Monday, Aug. 4. The French pharmaceutical company headquartered in Paris was reported to have offered to buy the US-based company after experiencing setbacks in its attempt to produce its own brand of COVID-19 vaccine.
As per CNBC, Sanofi will purchase all the available shares of the Massachusetts-headquartered mRNA therapeutics company at $38.00 per share. The total equity value is around $3.2 billion, and it will be paid in cash.
An insider who cannot be identified because of the confidentiality of the deal shared that Translate Bio’s board will hold a meeting to discuss the offer. Another source revealed that Sanofi’s executive directors also convened last Sunday to talk about the potential acquisition.
At any rate, it was said that the boards of the two companies gave their approval for the deal. Translate Bio’s chief executive officer, and the firm’s largest shareholder are reportedly backing the takeover offer by Sanofi, and this was confirmed through a joint statement.
“Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics,” Sanofi’s CEO, Paul Hudson, said in a press release. “A fully owned platform allows us to develop additional opportunities in the fast-evolving mRNA space and we will also be able to accelerate our existing partnered programs already under development.”
Hudson added that with Translate Bio, aside from vaccines, Sanofi’s goal is to unravel the potential of messenger ribonucleic acid (mRNA) in other medical fields, including immunology, oncology, and rare diseases.
Prior to this recent acquisition, Sanofi and Translate Bio have actually been working together since 2018, and last year, they teamed up to develop an mRNA-based vaccine for COVID-19. In the third quarter of this year, they are expecting to get provisional results of their Phase I/II clinical trial.
Meanwhile, Reuters reported that shares of Sanofi went up by more than 70% to over $50 in extended trading. The financial terms of the French firm’s offer were not disclosed at this time, and Translate Bio's market value has also soared to around $2.2 billion at the close on Monday.
